scPharmaceuticals Inc.
SCPH · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $16 | $12 | $12 | $10 |
| % Growth | 36.5% | -3.3% | 21.2% | – |
| Cost of Goods Sold | $5 | $3 | $4 | $3 |
| Gross Profit | $11 | $8 | $8 | $7 |
| % Margin | 68.8% | 70.5% | 67.4% | 67% |
| R&D Expenses | $4 | $5 | $3 | $4 |
| G&A Expenses | $0 | $0 | $1 | $0 |
| SG&A Expenses | $21 | $21 | $21 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $25 | $26 | $25 | $25 |
| Operating Income | -$14 | -$18 | -$16 | -$18 |
| % Margin | -89.1% | -151.1% | -134.5% | -181% |
| Other Income/Exp. Net | -$4 | -$2 | -$3 | -$17 |
| Pre-Tax Income | -$18 | -$20 | -$19 | -$35 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18 | -$20 | -$19 | -$35 |
| % Margin | -112.4% | -168% | -155.1% | -350.1% |
| EPS | -0.34 | -0.37 | -0.42 | -0.75 |
| % Growth | 8.1% | 11.9% | 44% | – |
| EPS Diluted | -0.34 | -0.37 | -0.42 | -0.75 |
| Weighted Avg Shares Out | 54 | 54 | 45 | 47 |
| Weighted Avg Shares Out Dil | 54 | 54 | 45 | 47 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $1 | $1 | $1 | $2 |
| Depreciation & Amortization | $0 | $0 | -$0 | -$0 |
| EBITDA | -$17 | -$18 | -$17 | -$33 |
| % Margin | -103.2% | -155.7% | -142.4% | -331.6% |